HS
SAGE

HighVista Strategies’s Sage Therapeutics SAGE Stock Holding History

HighVista Strategies’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,111
Closed -$757K – 137
2021
Q1 		$757K Buy
10,111
+430
+4% +$35.3K 0.56% 33
2020
Q4 		$838K Buy
9,681
+499
+5% +$36.8K 0.54% 40
2020
Q3 		$561K Buy
+9,182
New +$465K 0.41% 34

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HighVista Strategies's SAGE Position: Q2 2021 in Review

HighVista Strategies sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 10,111 shares — an estimated $757K sold.

HighVista Strategies first reported a position in SAGE in Q3 2020 and held it in 3 quarters. The position peaked at $838K in Q4 2020. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • HighVista Strategies reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 10,111 Sage Therapeutics shares in Q2 2021, an estimated $757K.
  • HighVista Strategies first reported a position in Sage Therapeutics in Q3 2020 and held it in 3 quarters.
  • HighVista Strategies's Sage Therapeutics position peaked at $838K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.